MedicalExpo E-Magazine

1 week ago | emag.medicalexpo.com | Camille Rustici

Can a small device under your mattress change the way we understand — and treat — sleep disorders? According to Mathilde Chevalier-Pruvo, Director of Health Vision and Public Affairs at Withings, the answer is yes. In this conversation, she explains how real-world data collected via smart sensors is revolutionizing sleep research, enabling earlier diagnoses of conditions like sleep apnea, hypertension, and even cognitive decline.

1 week ago | emag.medicalexpo.com | Erin Tallman

ABIVAX’s novel oral therapy, obefazimod, shows promising results in treating refractory ulcerative colitis by targeting upstream inflammatory pathways. In a webcast hosted on March 17, 2025, ABIVAX showcased their latest developments in ulcerative colitis (UC) treatment, presented by Dr. David T. Rubin, MD, a prominent gastroenterologist from the University of Chicago.

2 weeks ago | emag.medicalexpo.com | Erin Tallman

Rapid and comprehensive CT imaging is essential for detecting hidden trauma and life-threatening complications in elderly patients after even minor falls, ensuring timely diagnosis and intervention. Even a seemingly minor fall can result in life-threatening complications for elderly individuals, a population particularly vulnerable to hidden trauma. Falls are the leading cause of serious injury in adults over the age of 65, and the risks are even greater for those over 80.

4 weeks ago | emag.medicalexpo.com | Erin Tallman

At Forum Labo Paris 2025, Molecular Devices is at the forefront of technological innovation, showcasing its advanced tools for high-throughput analysis, cellular imaging, and 3D biological culture. With a focus on pushing the boundaries of what is possible in laboratory research, the company is demonstrating how its microplate readers, automated imaging platforms, and powerful software solutions are enabling scientists to streamline workflows and obtain more reliable, accurate results.

4 weeks ago | emag.medicalexpo.com | Erin Tallman

Organoids have emerged as a promising tool in biomedical research, offering more physiologically relevant models for studying human diseases. From 2020 to 2024, interest in organoid research has surged by 50%, particularly among major biomedical companies, as noted by Dr. Guillaume Frugier, European Applications Scientist Manager at Molecular Devices. During the Forum Labo Paris 2025 event, Dr. Frugier spoke of the evolution of interest as well as current challenges and solutions.